Home » Authors » Aaron Lorenzo

Aaron Lorenzo

Articles

ARTICLES

Syrrx’s Structural Proteomics At Heart Of Pharmacia Alliance

Jan. 25, 2002

By Aaron Lorenzo

Triangle Plans NDA For One Drug, Discontinues Another

Jan. 22, 2002

By Aaron Lorenzo

Triangle Plans NDA For One Drug, Discontinues Another

Jan. 22, 2002

By Aaron Lorenzo

LION Purchasing NetGenics In Stock Deal Worth $17.6M

Jan. 16, 2002

By Aaron Lorenzo

LION Purchasing NetGenics In Stock Deal Worth $17.6M

Jan. 16, 2002

By Aaron Lorenzo

Miravant's SnET2 Fails Phase III; Stock Price Drops 75 Percent

Jan. 15, 2002

By Aaron Lorenzo

Miravant Medical Technologies Inc. suffered a 75.6 percent stock drop Monday on negative Phase III data of an investigational drug to treat vision loss.

Miravant's SnET2 Fails Phase III; Stock Price Drops 75 Percent

Jan. 15, 2002

By Aaron Lorenzo

Miravant Medical Technologies Inc. suffered a 75.6 percent stock drop Monday on negative Phase III data of an investigational drug to treat vision loss.

IGEN Wins $505M From Roche In Court; Roche Plans To Appeal

Jan. 14, 2002

By Aaron Lorenzo

IGEN Wins $505M From Roche In Court; Roche Plans To Appeal

Jan. 14, 2002

By Aaron Lorenzo

Enzon, Inhale Enter Broad Deal On Pegylation, Licensing, Lawsuit

Jan. 9, 2002

By Aaron Lorenzo

View All Articles by Aaron Lorenzo

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for May 9, 2025.
100 days of uncertainty
BioWorld
The first 100 days of the Trump administration have been nothing short of chaotic, both in the U.S. and throughout the world. Shining a light through the...
Tenvie Therapeutics discovers new TMEM175 modulators
BioWorld Science
Tenvie Therapeutics Inc. has described endosomal/lysosomal proton channel TMEM175 modulators reported to be useful for the treatment of cancer, neurological...
AACR 2025: Induced proximity strategy, beyond degraders
BioWorld
Targeted protein degradation has yet to notch its first approval. But with more than two dozen agents now in clinical trials, the strategy’s ultimate clinical...